Another Actos Prediction Comes True & Lawsuits Begin

Back in February of this year we studied the oral diabetes drug, Actos. We had previously studied Avandia and found the starter back in 2004 for the lawsuits that eventually happened in 2008. A friend asked me why Avandia became so damaged while Actos seemed to escape the same fate even though we found that Actos had many concerns from cardiac problems to cancer risks. But the one thing that seemed to not haunt Actos was reported deaths attributed to Actos the way that deaths were attributed to Avandia.

That seems to have changed to today. We predicted that if patients and caregivers started to attribute deaths directly to Actos, that lawsuits would happen almost immediately. Avandia lawsuits took years to happen but the legal community has been looking for an Actos weakness for years. And we predicted that once they found it, the lawsuits would follow fast, furious and in large numbers.

The cancer risk problem that had Actos to be removed from the market in Germany and France in June and caused the FDA to increase warnings, is causing deaths from bladder cancer. Patients and caregivers are directly attributing fatal cancers and death to Actos.

One law firm is reporting that they represent 120 clients and every day that they will add 30 or more a week. Dozens of other firms are advertising for clients.

We see this development as the beginning of the end for Actos. Their combination product of Actos + alogliptin should be at risk as should the use of Actos for other indications such as multiple sclerosis.

If we deepen our prediction as lawsuits begin, we believe that Actos will lose FDA approval by end of the year. And the last TZD falls.